These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 27438814)

  • 1. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
    Zhang Q; Zhang X; You Q
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
    Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.
    Zhang J; Ji T
    J Mol Model; 2017 Jan; 23(1):1. PubMed ID: 27921184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
    Yao H; Sun Q; Zhu J
    Arch Pharm (Weinheim); 2016 Oct; 349(10):808-815. PubMed ID: 27624806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular insight into mutation-induced conformational change in metastasic bowel cancer BRAF kinase domain and its implications for selective inhibitor design.
    Zhao K; Zhou X; Ding M
    J Mol Graph Model; 2018 Jan; 79():59-64. PubMed ID: 29145034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.
    Liu T; Wang Z; Guo P; Ding N
    Eur Biophys J; 2019 Jan; 48(1):73-82. PubMed ID: 30218115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
    Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
    Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.
    Liu L; Lee MR; Kim JL; Whittington DA; Bregman H; Hua Z; Lewis RT; Martin MW; Nishimura N; Potashman M; Yang K; Yi S; Vaida KR; Epstein LF; Babij C; Fernando M; Carnahan J; Norman MH
    Bioorg Med Chem; 2016 May; 24(10):2215-34. PubMed ID: 27085672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.
    Waizenegger IC; Baum A; Steurer S; Stadtmüller H; Bader G; Schaaf O; Garin-Chesa P; Schlattl A; Schweifer N; Haslinger C; Colbatzky F; Mousa S; Kalkuhl A; Kraut N; Adolf GR
    Mol Cancer Ther; 2016 Mar; 15(3):354-65. PubMed ID: 26916115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the Binding of DFG-out Allosteric Inhibitors to B-Raf Kinase Using Molecular Dynamics and Free Energy Calculations.
    Coronel L; Granadino-Roldán JM; Pinto M; Tomas MS; Pujol MD; Rubio-Martinez J
    Curr Comput Aided Drug Des; 2015; 11(2):124-36. PubMed ID: 26135342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.
    Wang L; Zhu G; Zhang Q; Duan C; Zhang Y; Zhang Z; Zhou Y; Lu T; Tang W
    Org Biomol Chem; 2017 Apr; 15(16):3455-3465. PubMed ID: 28368067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
    Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
    Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
    Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
    Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf
    Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J
    Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
    Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
    Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF.
    Ham JM; Kim M; Kim T; Ryu SE; Park H
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type II Inhibitors Targeting CDK2.
    Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
    ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.